Mar 26 2012
Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, today launched a new custom dose feature in Europe and Canada for TheraSphere®, Nordion's Y-90 microsphere treatment for liver cancer. Nordion has also filed a request with the Food and Drug Administration for approval of the custom dose feature in the United States.
In addition to standard dose vial configurations, Nordion now offers an expanded range of TheraSphere treatment options with custom doses available in wider variety of increments. The custom doses are designed to provide greater treatment flexibility for physicians, save administration time and reduce product waste, while limiting unnecessary radiation exposure to patients and healthcare professionals.
Nordion has also enhanced its Treatment Window Illustrator tool to demonstrate how custom doses can be selected and compared to standard dose vial configurations.
Nordion is attending the Society of Interventional Radiology (SIR) Annual Scientific Meeting 2012, March 24-29, in San Francisco. Nordion representatives will be at Booth #1234 to talk about TheraSphere to physicians attending the conference. Nordion will host two "Eat and Be Educated" learning sessions at its booth:
Sunday, March 25, 12:15pm
How TheraSphere Y-90 Glass Microspheres Fits in Our Treatment Algorithm
Matthew Johnson, MD
Professor of Radiology and Surgery
Indiana University School of Medicine
Indianapolis, IN
Tuesday March 27, 12:15pm
TheraSphere Multi-Vessel Delivery
Siddharth Padia, MD
Assistant Professor, Interventional Radiologist
University of Washington - Harbourview Medical Center
Seattle, WA
Each session will be followed by a Nordion presentation on how to start a TheraSphere program.